Responsive Thalamic Neuromodulation for Drug-Resistant Epilepsy

ASSFN Breakfast Symposium

Explore the evolving role of responsive thalamic neuromodulation for drug-resistant epilepsy. Hear the latest on:

• Patient Selection & Thalamic Targeting for Focal Epilepsy
• 18-Month Results from the NAUTILUS Study for drug-resistant IGE
• Feasibility Study of Responsive Stimulation for Lennox-Gastaut Syndrome

Featured Speakers:

Mark Richardson, MD, PhD, Functional Neurosurgeon, Massachusetts General Hospital

John Rolston, MD, PhD, Functional Neurosurgeon, Brigham and Women's Hospital

Martha Morrell, MD, Chief Medical Officer, NeuroPace

Date and Location: 

Monday, June 1, 2026 | 7:00am – 7:55am EDT

Hilton Cleveland Downtown | Hope Ballroom E | 100 Lakeside Ave E, Cleveland, OH

Invitation only, HCPs only. Space is limited, non-transferable. Breakfast will be provided. Expenses will be reported in accordance with the Sunshine Act. Rx Only. The RNS® System is an adjunctive therapy for adults with refractory, partial onset seizures with no more than 2 epileptogenic foci. See important safety information at http://www.neuropace.com/safety

For the NAUTILUS Study & LGS Study: CAUTION Investigational device. Limited by United States law to investigational use for Idiopathic Generalized Epilepsy and LGS. ©2026 NeuroPace, Inc. All rights reserved. NeuroPace, the NeuroPace logo, and RNS are registered trademarks of NeuroPace, Inc. Mountain View, CA 94043. NP 260032 Rev1 / Date 2026-03